A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.
OBJECTIVE
The aim of this study was to describe a case of sterile endophthalmitis after repeated intravitreal bevacizumab injections for the treatment of choroidal neovascularization secondary to angioid streaks.


METHODS
This study was done as a case report.


RESULTS
A 57-year-old man who received a third injection of intravitreal bevacizumab for the treatment of choroidal neovascularization owing to angioid streaks developed sterile endophthalmitis. The patient's condition improved after hourly topical steroid and antibiotic drops without a sequele.


CONCLUSIONS
The intravitreal injection of bevacizumab has the potential for the development of sterile endophthalmitis. The patients should be warned against this possible adverse reaction, especially after repeated injections.
Yenerel
N Melda
NM
Ophthalmology Department, Yeditepe University Eye Hospital, Istanbul, Turkey. meldayen@hotmail.com
Dinc
Umut A
UA
Gorgun
Ebru
E
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000793:Angioid Streaks / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D002939:Ciprofloxacin / Q000627:therapeutic use; D009877:Endophthalmitis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D014822:Vitreous Body / Q000502:physiology*
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002939:Ciprofloxacin